Phenylalanin-Serin

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Phenylalanin-Serin
• 英文别名: N-phenylalanyl-serine；Inaktives Phenylalanyl-serin；N-Phenylalanyl-serin；2-[(2-azaniumyl-3-phenylpropanoyl)amino]-3-hydroxypropanoate
• 化学式: C₁₂H₁₆N₂O₄
• mdl: MFCD13248053
• 分子量: 252.27
• InChiKey: ROHDXJUFQVRDAV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.7
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  113
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 barium dihydroxide 作用下， 生成 Phenylalanin-Serin
  参考文献：
  名称：

  Bergmann; Miekeley, Justus Liebigs Annalen der Chemie, 1927, vol. 458, p. 66

  摘要：

  DOI：

文献信息

• Blood based biomarkers for diagnosing atherosclerotic coronary artery disease
  申请人：Global Genomics Group, LLC

  公开号：US10254272B2

  公开（公告）日：2019-04-09

  The invention, in some aspects, relates to methods for evaluating a human subject for having atherosclerotic coronary artery disease (ASCAD) or as having a coronary atherosclerotic plaque. In some aspects, the invention relates to methods and kits useful for diagnosing, classifying, profiling and treating atherosclerotic CAD and or a coronary atherosclerotic plaque.

  在某些方面，本发明涉及评估人体是否患有冠状动脉粥样硬化性疾病（ASCAD）或冠状动脉粥样硬化斑块的方法。在某些方面，本发明涉及用于诊断、分类、剖析和治疗动脉粥样硬化性冠状动脉疾病和或冠状动脉粥样硬化斑块的方法和试剂盒。
• Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
  申请人：Metabolon, Inc.

  公开号：US10267777B2

  公开（公告）日：2019-04-23

  Methods are described herein for small molecule biochemical profiling of an individual subject for diagnosis of a disease or disorder, facilitating diagnosis of a disease or disorder, and/or identifying an increased risk of developing a disease or disorder in the individual subject. Aberrant levels of small molecules present in a sample from an individual subject are identified and diagnostic information relevant to the individual subject is obtained based on the identified aberrant levels. The obtained diagnostic information includes one or more of an identification of at least one biochemical pathway associated with the identified subset of the small molecules having aberrant levels, an identification at least one disease or disorder associated with the identified subset of the small molecules having aberrant levels, and an identification of at least one recommended follow up test associated with the identified subset of the small molecules having aberrant levels.

  本文描述了对个体受试者进行小分子生化分析的方法，以诊断疾病或失调，促进疾病或失调的诊断，和/或确定个体受试者罹患疾病或失调的风险增加。确定个体受试者样本中存在的小分子的异常水平，并根据确定的异常水平获得与个体受试者相关的诊断信息。所获得的诊断信息包括：至少一个生化途径的鉴定，该生化途径与所鉴定的具有异常水平的小分子子集相关；至少一种疾病或紊乱的鉴定，该疾病或紊乱与所鉴定的具有异常水平的小分子子集相关；至少一种推荐的后续检测的鉴定，该检测与所鉴定的具有异常水平的小分子子集相关。
• PEPTIDES AYANT DES POPRIETES IMMUNOSTIMULANTES ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：INSTITUT PASTEUR

  公开号：EP0036420A1

  公开（公告）日：1981-09-30
• BIOMARKERS FOR KIDNEY CANCER AND METHODS USING THE SAME
  申请人：Metabolon, Inc.

  公开号：EP2788763A2

  公开（公告）日：2014-10-15
• CONTROL OF WHOLE BODY ENERGY HOMEOSTASIS BY MICRORNA REGULATION
  申请人：Miragen Therapeutics, Inc.

  公开号：EP2763703B1

  公开（公告）日：2018-02-14